Morgan Stanley Trims Accolade (NASDAQ:ACCD) Goal Worth to $11.00

Accolade (NASDAQ:ACCD – Get Score) had its value goal reduce by Morgan Stanley from $12.00 to $11.00 in a observe issued to buyers on Friday, Benzinga studies. The brokerage at the moment has an “equal weight” ranking on the inventory. Morgan Stanley’s value goal suggests a possible upside of 49.25% from the corporate’s earlier shut.

Numerous different analysis analysts additionally lately commented on the corporate. SVB Leerink upped their value goal on Accolade from $8.00 to $13.00 and gave the inventory a “market carry out” ranking in a analysis observe on Friday, October seventh. Canaccord Genuity Group elevated their value goal on Accolade from $12.00 to $15.00 and gave the inventory a “purchase” ranking in a analysis observe on Monday, October third. Canaccord Genuity Group elevated their value goal on Accolade from $12.00 to $15.00 in a analysis observe on Monday, October third. The Goldman Sachs Group elevated their value goal on Accolade from $14.50 to $16.00 and gave the inventory a “purchase” ranking in a analysis observe on Friday, October seventh. Lastly, Piper Sandler elevated their value goal on Accolade from $12.00 to $13.00 and gave the inventory an “chubby” ranking in a analysis observe on Tuesday, October 4th. Seven equities analysis analysts have rated the inventory with a maintain ranking and 7 have assigned a purchase ranking to the corporate. In accordance with information from MarketBeat, Accolade has a mean ranking of “Average Purchase” and a consensus value goal of $14.73.

Accolade Worth Efficiency

Shares of NASDAQ ACCD opened at $7.37 on Friday. Accolade has a twelve month low of $4.61 and a twelve month excessive of $24.95. The corporate has a present ratio of three.33, a fast ratio of three.33 and a debt-to-equity ratio of 0.56. The corporate has a market capitalization of $530.20 million, a price-to-earnings ratio of -1.28 and a beta of 1.36. The enterprise has a 50 day easy shifting common of $8.66 and a 200-day easy shifting common of $9.94.

Accolade (NASDAQ:ACCD – Get Score) final issued its quarterly earnings information on Thursday, October sixth. The corporate reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.05. The agency had income of $87.64 million throughout the quarter, in comparison with the consensus estimate of $82.86 million. Accolade had a unfavourable return on fairness of 26.12% and a unfavourable internet margin of 114.56%. The agency’s income was up 19.6% on a year-over-year foundation. Throughout the identical interval within the prior 12 months, the enterprise earned ($0.67) EPS. As a gaggle, equities analysis analysts anticipate that Accolade will publish -6.52 earnings per share for the present 12 months.

Institutional Traders Weigh In On Accolade

A number of hedge funds have lately modified their holdings of the inventory. Quantamental Applied sciences LLC lifted its holdings in shares of Accolade by 17.5% throughout the second quarter. Quantamental Applied sciences LLC now owns 11,926 shares of the corporate’s inventory valued at $88,000 after buying a further 1,780 shares over the past quarter. American Worldwide Group Inc. lifted its holdings in shares of Accolade by 7.9% throughout the second quarter. American Worldwide Group Inc. now owns 27,333 shares of the corporate’s inventory valued at $202,000 after buying a further 2,003 shares over the past quarter. New York State Widespread Retirement Fund lifted its holdings in shares of Accolade by 7.5% throughout the third quarter. New York State Widespread Retirement Fund now owns 38,984 shares of the corporate’s inventory valued at $445,000 after buying a further 2,736 shares over the past quarter. Advisors Capital Administration LLC lifted its holdings in shares of Accolade by 6.7% throughout the third quarter. Advisors Capital Administration LLC now owns 48,644 shares of the corporate’s inventory valued at $465,000 after buying a further 3,047 shares over the past quarter. Lastly, Rhumbline Advisers lifted its stake in Accolade by 6.7% within the 1st quarter. Rhumbline Advisers now owns 52,869 shares of the corporate’s inventory value $928,000 after buying a further 3,312 shares within the final quarter. 79.01% of the inventory is owned by hedge funds and different institutional buyers.

Accolade Firm Profile

(Get Score)

Accolade, Inc, along with its subsidiaries, develops and gives technology-enabled options that assist individuals to grasp, navigate, and make the most of the healthcare system and their office advantages in america. The corporate presents a platform with cloud-based know-how and multimodal help from a workforce of well being assistants and clinicians, together with nurses, doctor medical administrators, and behavioral well being specialists.

Featured Articles

Analyst Recommendations for Accolade (NASDAQ:ACCD)

This on the spot information alert was generated by narrative science know-how and monetary information from MarketBeat as a way to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to [email protected]

Earlier than you think about Accolade, you will need to hear this.

MarketBeat retains observe of Wall Road’s top-rated and finest performing analysis analysts and the shares they suggest to their shoppers each day. MarketBeat has recognized the 5 shares that prime analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Accolade wasn’t on the record.

Whereas Accolade at the moment has a “Average Purchase” ranking amongst analysts, top-rated analysts imagine these 5 shares are higher buys.

View The 5 Shares Right here

Leave a Reply